###begin article-title 0
Apolipoprotein E polymorphisms and primary glaucoma in Saudis
###end article-title 0
###begin p 1
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Purpose
###end title 2
###begin p 3
###xml 37 41 37 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 200 208 <span type="species:ncbi:9606">patients</span>
The frequencies of apolipoprotein E (APOE) alleles and genotypes were examined in 230 Saudi subjects including primary open-angle glaucoma (POAG; n=60) and primary angle-closure glaucoma (PACG; n=40) patients as well as 130 control subjects.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 102 106 102 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 28 36 <span type="species:ncbi:9606">patients</span>
The presence of glaucoma in patients was based on clinical examination and/or ophthalmic records. The APOE allele frequency (epsilon2, epsilon3, and epsilon4) was studied by polymerase chain reaction (PCR) followed by reverse-hybridization and restriction fragment length polymorphism techniques.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 1194 1198 1086 1090 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 141 149 <span type="species:ncbi:9606">patients</span>
###xml 345 353 <span type="species:ncbi:9606">patients</span>
###xml 518 526 <span type="species:ncbi:9606">patients</span>
###xml 724 732 <span type="species:ncbi:9606">patients</span>
###xml 920 928 <span type="species:ncbi:9606">patients</span>
###xml 982 990 <span type="species:ncbi:9606">patients</span>
###xml 1149 1156 <span type="species:ncbi:9606">patient</span>
Analysis of data showed a complete absence of epsilon2 allele and a significantly lower frequency of the epsilon3 allele in primary glaucoma patients (90.5%) compared to the control subjects (95.7%, p=0.034, relative risk [RR]=0.473, protective fraction [PF]=0.318). The frequency of the epsilon4 allele was significantly higher in the glaucoma patients (9.5%) compared to the control subjects (4.2%, p=0.034, RR=2.169, etiological fraction [EF]=0.329). The epsilon3/epsilon3 genotype was more common in controls than patients (p=0.060, RR=0.465, PF=0.322). The difference in genotype (epsilon3/epsilon4) was not statistically significant between the two groups (p=0.283). Genotype epsilon4/epsilon4 was found only in 3% of patients while being completely absent in the controls (p=0.080). The genotypes, epsilon2/epsilon2, epsilon2/epsilon3, and epsilon2/epsilon4, were absent in both the test and control groups. When patients were divided on the basis of types of glaucoma, POAG patients had a significantly higher frequency of epsilon4 allele and epsilon4/epsilon4 genotype than controls whereas there was no significant difference between PACG patient and control groups in frequencies of APOE alleles and genotypes.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
This study indicates that the epsilon4 allele may be associated with POAG and could be a risk factor while epsilon3 may be protective for POAG, and APOE polymorphisms may not be associated at all with PACG in Saudis.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 215 216 215 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 217 218 217 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 416 417 416 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 418 419 418 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 527 528 527 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 981 982 981 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 160 166 <span type="species:ncbi:9606">people</span>
Primary glaucoma (PG) is one of the most common eye diseases that may potentially result in bilateral blindness. It has been estimated that nearly 66.8 million people worldwide (around 2%) are affected by glaucoma [1,2]. The disease is characterized by optic nerve atrophy with an excavated optic nerve head and progressive visual field loss. The loss of retinal ganglion cells is the typical pathology in glaucoma [3,4]. Although elevation of intraocular pressure (IOP) is often related to the optic nerve damage in glaucoma [5], factors other than IOP are likely to have a role in the pathogenesis of glaucomatous optic neuropathy, particularly in individuals with normal tension glaucoma (NTG). Evidence from population and family studies supports heredity of glaucoma to be a complex trait. It is a genetically heterogeneous disorder attributed to the effects of individual causative mutations as well as interactions of multiple genes with a variety of environmental factors [6].
###end p 11
###begin p 12
###xml 186 187 186 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 429 430 429 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 633 634 633 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 1038 1040 1020 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 1523 1525 1421 1423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 1526 1528 1424 1426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 694 700 <span type="species:ncbi:9606">humans</span>
###xml 1062 1067 <span type="species:ncbi:9606">human</span>
Apolipoprotein E (APOE) is the major apolipoprotein in the central nervous system, which plays an important role in the uptake and redistribution of cholesterol within neuronal network [7]. APOE is synthesized by Muller cells (the predominant glial cells of the retina), released into the vitreous, and then transported into the optic nerve through anterograde rapid transport where it has an important role in axonal nutrition [8]. It has been suggested that APOE plays a role in neuronal survival following ischemia and other chemical insults and that a particular APOE isoform may be related to neuronal degeneration in glaucoma [9]. The gene encoding APOE has three polymorphic variants in humans, these variants are designated as epsilon2, epsilon3, and epsilon4. These variants differ from one another by the presence of either a C or T nucleotide at codons 112 and 158. These three alleles encode different APOE isoforms, which vary significantly in structure and function including receptor binding capacity and lipid metabolism [10]. As each individual human being carries two allelic copies in a gene, six possible genotypes (epsilon2/epsilon2, epsilon3/epsilon3, epsilon2/epsilon3, epsilon3/epsilon4, epsilon2/epsilon4, and epsilon4/epsilon4) are formed by different combinations of these three alleles. The frequency of these genotypes differ significantly among different ethnic groups. However, APOE epsilon3/epsilon3 is the most predominant genotype and e3 the most common allele in majority of populations [11,12].
###end p 12
###begin p 13
###xml 68 72 68 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 198 199 198 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 336 337 336 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 356 358 356 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 359 361 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 376 378 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 428 430 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 431 433 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 509 513 509 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
Earlier studies clearly point toward a possible association between APOE alleles and glaucoma. However, the results of these studies are contradictory. Some investigators show positive association [9,13,14] while others show no link at all [15-17]. More over, earlier studies were mainly restricted to White populations from Australia [9], United Kingdom [15,16], and Sweden [17] with only few reports from other ethnic groups [13,14]. So far, no attempt has been made to study a possible association between APOE alleles and glaucoma in a Saudi population.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
Subjects
###end title 15
###begin p 16
###xml 64 68 64 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 732 733 724 725 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">.</bold>
###xml 130 138 <span type="species:ncbi:9606">patients</span>
###xml 171 179 <span type="species:ncbi:9606">patients</span>
###xml 386 393 <span type="species:ncbi:9606">patient</span>
The present study was undertaken to evaluate the association of APOE alleles and genotype with glaucoma in Saudi primary glaucoma patients. A total of 100 unrelated Saudi patients with primary glaucoma (primary open-angle glaucoma [POAG] and primary angle-closure glaucoma [PACG]) were recruited from the Ophthalmology Clinic of the Riyadh Military Hospital (Riyadh, Saudi Arabia). The patient group consisted of 47 males and 53 females with the age at diagnosis ranging from 30 to 78 years (mean+/-SD: 58+/-14.4 years). The control group consisted of 130 unrelated subjects with 102 males and 28 females and their ages ranging from 20 to 58 years (mean+/-SD: 45+/-11.6 years). The diagnosis of PG was based on clinical observations.
###end p 16
###begin p 17
A comprehensive eye examination was done that included best-corrected visual acuity (BCVA) measurements using the logarithm of the minimum angle of resolution (logMAR) 4-m charts (Light House Low Vision Products, New York, NY), applanation tonometry, gonioscopy, dilated fundus examination, optic disc photography, and visual field (VF) examination. On gonioscopy, an angle was considered occludable if the pigmented trabecular meshwork was not visible at an angle greater than 180degrees in dim illumination. Laser iridotomy was performed in subjects with occludable angles after consent was obtained. The ocular biometric measurements were carried out on the following day.
###end p 17
###begin title 18
Visual fields
###end title 18
###begin p 19
###xml 1523 1525 1511 1513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
Automated VFs were performed for all subjects with a BCVA of 4/16 (logMAR 0.6) or better using frequency-doubling perimetry (Carl Zeiss Meditec Inc., Dublin, CA). All eligible subjects underwent C-20-1 screening (if the results were unreliable or abnormal, the test was repeated) and the N-30 threshold test. The reliability criteria were no fixation or false-positive errors for the C-20-1 screening test and less than 20% fixation errors and less than 33% false-positive and false-negative errors for the threshold N-30 test. Visual fields with no depressed points to any level of sensitivity were considered to be normal. A provisional diagnosis of suspected glaucoma was made when the subject had one or more of the following conditions: intraocular pressure (IOP) >/=21 mmHg in either eye, vertical cup-to-disc ratio (VCDR) >/=0.7 in either eye or cup-to disc ratio (CDR) asymmetry >/=0.2, and focal thinning, notching, or a splinter hemorrhage. All these subjects were asked to perform a threshold VF test using the Swedish interactive threshold algorithm Standard 30-2 program (model 750, Carl Zeiss Meditec Inc.). A glaucomatous field defect was diagnosed using a single reliable threshold VF examination of the central 30degrees (Swedish interactive threshold algorithm Standard 30-2). The field was considered to be abnormal if the Glaucoma Hemifield test results were outside normal limits and if three or more abnormal contiguous non-edge points (except the nasal horizontal meridian) were depressed to p<0.05 [18]. Reliability criteria were as recommended by the instrument's algorithm (fixation losses <20%; false-positive and false-negative <33%).
###end p 19
###begin title 20
Diagnostic definitions
###end title 20
###begin p 21
###xml 281 283 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 1009 1016 <span type="species:ncbi:9606">persons</span>
The distribution of VCDR and IOP was obtained from those subjects with reliable and normal supra-threshold VF testing using frequency-doubling perimetry. Cases of glaucoma were defined using the International Society of Geographical and Epidemiologic Ophthalmology classification [19]. Glaucoma was classified according to three levels of evidence. In category 1, diagnosis was based on structural and functional evidence. Using the Swedish interactive threshold algorithm 30-2, it required CDR or CDR asymmetry greater than 97.5th percentile for the normal population, or a neuroretinal rim width reduced to 0.1 CDR (between 10- and 1-o'clock or 5- and 7-o'clock) with a definite VF defect consistent with glaucoma. Category 2 was based on advanced structural damage with unproven field loss. This included those subjects in whom VFs could not be determined or were unreliable, and subjects  with CDR or CDR asymmetry greater than 99.5th percentile for the normal population. Lastly, category 3 consisted of persons whose optic discs could not be examined because of media opacities and with an IOP greater than 99.5th percentile for the normal population.
###end p 21
###begin p 22
###xml 181 183 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 276 278 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 424 426 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
Blindness was defined as a best-corrected logMAR visual acuity of less than 2/40 (log MAR 1.3) and/or constriction of the VF to less than 10degrees from fixation in the better eye [20]. Hyperopia was defined as spherical equivalent greater than 0.50 diopters in a phakic eye [21]. Diabetes mellitus was detected based on the current use of antidiabetic medication and/or a random blood glucose level greater than 200 mg/dl [22].
###end p 22
###begin p 23
###xml 27 35 <span type="species:ncbi:9606">patients</span>
###xml 123 131 <span type="species:ncbi:9606">patients</span>
###xml 311 319 <span type="species:ncbi:9606">patients</span>
###xml 764 772 <span type="species:ncbi:9606">Patients</span>
Thus, the primary glaucoma patients were separated into two groups (POAG and PACG) using the following criteria. POAG: The patients with open anterior chamber angles on gonioscopy, typical glaucomatous cupping of optic disc and visual field defects characteristic of glaucoma were classified as POAG. PACG: The patients with partially or totally closed anterior chamber angle (appositional angle closure or synechiae in angle) along with damaged glaucomatous optic disc or defective glaucomatous visual field were classified as PACG. Subjects with any sign of secondary angle closure (e.g., uveitis, lens related glaucoma; microspherophakia; evidence of neovascularization in the angle and associated retinal ischemia or congenital angle anomalies) were excluded. Patients with signs of intracranial disease that would cause optic nerve atrophy in X-ray computerized tomography or magnetic resonance imaging were also excluded.
###end p 23
###begin p 24
###xml 218 230 <span type="species:ncbi:9606">participants</span>
Venous blood was collected and stored at -20 degreesC before the extraction of DNA. The study protocol was approved by the ethics committee of Riyadh Military Hospital, and informed consent was obtained from all study participants.
###end p 24
###begin title 25
Genotyping
###end title 25
###begin p 26
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 81 84 81 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM </sup>
###xml 643 647 643 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 813 817 813 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 866 870 866 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
The genotypes of the APOE polymorphisms were determined using the ApoE StripAssayTM kit (ViennaLab Labordiagnostika GmbH, Vienna, Austria), which is based on polymerase chain reaction (PCR) and reverse-hybridization techniques. The procedure included three steps: (1) DNA isolation, (2) PCR amplification using biotinylated primers, and (3) hybridization of amplification product to a test strip containing allele-specific oligonucleotide probes immobilized as an array of parallel lines. Bound biotinylated sequences were detected using streptavidin-alkaline phosphatase and color substrates. To cross-check the results, the genotypes of the APOE polymorphisms were also determined by PCR and restriction fragment length polymorphism (RFLP) technique. Primers were designed on the basis of the sequence data for APOE available in  to amplify the coding sequence of APOE. PCR was performed using PuRe Taq Ready-To-Go PCR Beads (Amersham Biosciences, Piscataway, NJ) with the following primers: forward primer: 5- GAC GCG GGC ACG GCT GTC CAA GGA GCT GCA GGC GAC GCA GGC CCG GCT GGA CGC GGA CAT GGA GGA-3 and reverse primer: 5 - AGG CCA CGC TCG ACG CCC TCG CGG GCC CCG GCC TGG TAC ACT-3.
###end p 26
###begin p 27
###xml 781 785 762 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 1196 1204 <span type="species:ncbi:9606">patients</span>
Genomic DNA was extracted from whole blood using a commercial kit (QIAmp; Qiagen, Hilden, Germany). Genomic DNA (200-300 ng) was used as a template in 25 mul reactions. Genomic DNA was amplified for 40 cycles. Each cycle consisted of 94 degreesC for 30 s, 68 degreesC for 10 s, and 72 degreesC for 1 min. PCR products obtained were separated by electrophoresis on 1.5% agarose gel in Tris-acetic acid-EDTA (TAE) buffer and visualized by ethidium bromide fluorescence. Fragments with the expected size were cut from the gel and purified using GFX PCR DNA Gel band purification kit (Amersham). Purified DNA was digested with the CfoI (HhaI) enzyme and separated by agarose gel electrophoresis to identify the genotype. On the basis of size and number of various fragments generated, APOE genotypes were determined as epsilon2/epsilon2 with 144 bp and 96 bp fragments; epsilon3/epsilon3 with 144 bp and 48 bp fragments; epsilon4/ epsilon4 with 72 bp and 48 bp fragments; epsilon2/epsilon3 with 144 bp, 96 bp, and 48 bp fragments; epsilon3/ epsilon4 with 144 bp, 72 bp, and 48 bp fragments; and epsilon2/epsilon4 with 144 bp, 96 bp, 72 bp, and 48 bp fragments. The prevalence of various genotypes in patients and controls was determined. Complete matching of results was obtained following both of the above mentioned procedures.
###end p 27
###begin title 28
Statistical analysis
###end title 28
###begin p 29
###xml 415 417 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 89 97 <span type="species:ncbi:9606">patients</span>
###xml 523 531 <span type="species:ncbi:9606">patients</span>
Frequencies of various alleles and genotypes for each polymorphism were compared between patients and controls and then analyzed by Fisher's exact test (p values less than 0.05 were considered significant). The strength of the association of disease with respect to a particular antigen is expressed by an odds ratio interpreted as relative risk (RR) according to Woolf's method as outlined by Schallreuter et al. [23]. The RR was calculated only for those alleles and genotype that were increased or decreased in glaucoma patients as compared to normal Saudis.
###end p 29
###begin title 30
Etiologic fraction
###end title 30
###begin p 31
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
The etiologic fraction (EF) indicates the hypothetical genetic component of the disease. Values greater than 0.0 were considered significant. It was calculated for positive association (RR>1) [24].
###end p 31
###begin title 32
Preventive fraction
###end title 32
###begin p 33
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
The preventive fraction (PF) indicates the hypothetical protective effect of one specific antigen for the disease. It was calculated for negative association (RR<1) [24]. Values less than 1.0 indicated the protective effect of the genotype/allele against the manifestation of the disease.
###end p 33
###begin title 34
Results
###end title 34
###begin p 35
###xml 14 22 <span type="species:ncbi:9606">patients</span>
Out of 100 PG patients, 60 were diagnosed as having POAG and 40 as having PACG. Diagnosis of POAG was based on category 1 in nine subjects (15%) and category 2 in 51 subjects (85%). Between category 1 and category 2, there were no significant differences in age, IOP, or gender distribution. One subject was blind in both eyes, and one subject had unilateral blindness due to POAG. There were 40 subjects with PACG. Diagnosis was based on category 1 in 10 subjects (25%), category 2 in 28 subjects (70%), and category 3 in two subjects (5%). Two subjects (5%) were bilaterally blind and three (7.5%) were unilaterally blind, all due to PACG.
###end p 35
###begin p 36
###xml 25 29 25 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 114 121 114 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 130 137 130 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t6">Table 6</xref>
###xml 541 548 523 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 62 70 <span type="species:ncbi:9606">patients</span>
###xml 216 224 <span type="species:ncbi:9606">patients</span>
###xml 391 399 <span type="species:ncbi:9606">patients</span>
###xml 513 520 <span type="species:ncbi:9606">patient</span>
The frequency results of APOE alleles and genotypes in the PG patients and the control subjects are summarized in Table 1 through Table 6. The frequency of the epsilon3 allele was significantly lower in the glaucoma patients (90%) than in the control subjects (95.7%, p=0.034, RR=0.473, PF=0.318). In contrast, the frequencies of the epsilon4 allele was significantly higher in the glaucoma patients than in the controls (9.5% versus 4.2%, p=0.034, RR=2.169, EF=0.329). The allele epsilon2 was absent in both the patient and control groups (Table 1).
###end p 36
###begin title 37
###xml 52 60 <span type="species:ncbi:9606">patients</span>
Distribution of APOE allele frequencies in glaucoma patients and matched controls.
###end title 37
###begin p 38
Number of subjects=n. Values with  asterisk (last column) correspond to etiological fraction (EF) while values without asterisk indicate  protective fraction (PF).
###end p 38
###begin title 39
###xml 16 20 16 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 56 64 <span type="species:ncbi:9606">patients</span>
Distribution of APOE genotype and allele frequencies in patients with PACG and matched controls.
###end title 39
###begin p 40
Number of subjects=n; values are indicated as n (%). Values with  asterisk (last column) correspond to etiological fraction (EF) while values without asterisk indicate  protective fraction (PF).
###end p 40
###begin p 41
###xml 34 38 34 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 93 100 93 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 1277 1284 1145 1152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3">Table 3</xref>
###xml 65 72 <span type="species:ncbi:9606">patient</span>
###xml 205 213 <span type="species:ncbi:9606">patients</span>
###xml 497 505 <span type="species:ncbi:9606">patients</span>
###xml 753 761 <span type="species:ncbi:9606">patients</span>
###xml 1170 1178 <span type="species:ncbi:9606">patients</span>
Our study on various genotypes of APOE also showed variations in patient and control groups (Table 2). The prevalence of epsilon3/epsilon3, epsilon3/epsilon4, and epsilon4/epsilon4 was 84%, 13%, and 3% in patients and 91.5%, 8.4%, and 0% in the control group, respectively. Though the epsilon3/epsilon3 genotype was more common in both the test and control Saudi population, the statistical analysis of data showed a nearly significant difference in epsilon3/epsilon3 genotype frequencies between patients and controls (p=0.060, RR=0.465, PF=0.322). The difference in the frequencies of the second common genotype (epsilon3/epsilon4) was not statistically significant between the two groups (p=0.283). Genotype epsilon4/epsilon4 was found only in 3% of patients while being completely absent in the controls (p=0.080). The genotypes epsilon2/epsilon2, epsilon2/epsilon3, and epsilon2/epsilon4 were absent in both the groups. These results indicated that the epsilon4 allele is associated with glaucoma and can be a risk factor while the epsilon3 allele may be protective in Saudis. The frequencies of various genotypes and alleles were almost similar in male and female patients, clearly indicating that gender plays no role in genotype/allele distributions among populations (Table 3).
###end p 41
###begin title 42
###xml 16 20 16 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 54 62 <span type="species:ncbi:9606">patients</span>
Distribution of APOE genotype frequencies in glaucoma patients and matched controls.
###end title 42
###begin p 43
Number of subjects=n. Values with  asterisk (last column) correspond to etiological fraction (EF) while values without asterisk indicate  protective fraction (PF).
###end p 43
###begin title 44
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 81 89 <span type="species:ncbi:9606">patients</span>
Comparison of APOE genotypes and alleles frequencies in male and female glaucoma patients.
###end title 44
###begin p 45
Number of subjects=n.
###end p 45
###begin p 46
###xml 27 31 27 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 116 123 116 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t4">Table 4</xref>
###xml 525 532 483 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t5">Table 5</xref>
###xml 656 660 608 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 775 782 727 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t6">Table 6</xref>
###xml 267 275 <span type="species:ncbi:9606">patients</span>
###xml 465 473 <span type="species:ncbi:9606">patients</span>
Though the distribution of APOE genotypes and alleles was not significantly different in the two types of glaucoma (Table 4), significant difference was found in the frequencies of the epsilon4/epsilon4 genotype and the epsilon4 and epsilon3 alleles between the POAG patients and controls when each glaucoma group was compared with the controls separately. The frequencies of the epsilon4/epsilon4 genotype and the epsilon4 allele were significantly higher in POAG patients than in controls (p=0.03 and p=0.02, respectively; Table 5). The frequency of the epsilon3 allele was significantly higher in controls (p=0.02). Moreover, the frequencies of various APOE genotypes and alleles differed between PACG and controls, but the differences were not statistically significant (Table 6), indicating that the epsilon4/epsilon4 genotype and epsilon4 allele are only significantly associated with POAG and not with PACG in Saudis.
###end p 46
###begin title 47
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 54 62 <span type="species:ncbi:9606">patients</span>
Comparison of APOE genotype and allele frequencies in patients with POAG  and PACG.
###end title 47
###begin p 48
Number of subjects=n; values are indicated as n (%).
###end p 48
###begin title 49
###xml 16 20 16 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 56 64 <span type="species:ncbi:9606">patients</span>
Distribution of APOE genotype and allele frequencies in patients with POAG and matched controls.
###end title 49
###begin p 50
Number of subjects=n; values are indicated as n (%). Values with  asterisk (last column) correspond to etiological fraction (EF) while values without asterisk indicate  protective fraction (PF).
###end p 50
###begin title 51
Discussion
###end title 51
###begin p 52
###xml 61 65 61 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 242 246 224 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 385 387 349 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 388 390 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r31">31</xref>
###xml 520 524 484 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 696 700 654 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 857 859 809 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r32">32</xref>
###xml 599 604 <span type="species:ncbi:9606">human</span>
The results of this study showed the complete absence of the APOE epsilon2 allele but a very high frequency (95.7%) of epsilon3. The frequency of epsilon4 (known as the thrifty allele) was 4.3% in this Saudi population. Global studies on the APOE locus have shown highly significant variations in the allele frequencies of epsilon2 (0%-12%), epsilon3 (75%-90%), and epsilon4 (6%-20%) [25-31]. The reason for the dissimilar findings in different populations is far from clear and may reflect a regional difference in the APOE genotype frequencies. The epsilon3 allele is the most frequent in all the human groups, especially in populations with a long established agricultural economy whereas the APOE epsilon4 allele remains higher in populations where the economy of foraging still exists or where the food supply is/was scarce and sporadically available [32].
###end p 52
###begin p 53
###xml 166 173 154 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 501 503 465 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 750 752 702 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r34">34</xref>
###xml 753 755 705 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
###xml 910 912 856 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r34">34</xref>
###xml 1148 1150 1082 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
###xml 135 142 <span type="species:ncbi:9606">patient</span>
###xml 278 286 <span type="species:ncbi:9606">patients</span>
###xml 563 571 <span type="species:ncbi:9606">patients</span>
Results of the present study revealed significant differences in the frequencies of epsilon3 and epsilon4 alleles between the glaucoma patient and the control group (Table 1). The epsilon3 allele was more common in controls while the epsilon4 allele was predominant in glaucoma patients, suggesting that the inheritance of the epsilon4 allele might be a risk factor whereas epsilon3 may exert a protective effect for glaucoma in the Saudi population. Our findings are in agreement with Yilmaz et al. [33] who reported a protective role of APOE epsilon3 allele in patients with exfoliation syndrome (a disease closely associated with glaucoma) in the Turkish population. The neuroprotective effect of epsilon3 is evident from several earlier studies [34,35]. APOE has an isoform-specific effect on neuronal growth with epsilon3 stimulating neuronal elongation and neurite outgrowth on the dorsal root ganglion [34]. In individuals with acute cerebral ischemia such as an intracerebral hemorrhage, the epsilon3 allele confers a much higher rate of survival and functional recovery whereas epsilon4 leads to a higher rate of disability and mortality [35].
###end p 53
###begin p 54
###xml 187 188 181 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 307 309 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r36">36</xref>
###xml 463 465 445 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r37">37</xref>
###xml 500 504 482 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
Moreover, the results of this study clearly suggest that the presence of epsilon4 has a negative impact as its presence was found to be associated with high risk of POAG. Vickers et al. [9] also reported an association between the epsilon4 allele and NTG in the Tasmanian population. Recently, Yaun et al. [36] reported that the epsilon4 allele may be a latent risk factor in developing primary glaucoma in the Chinese population. On the other hand, Liew et al. [37] found a weak association between APOE epsilon4 and retinal microvascular degeneration.
###end p 54
###begin p 55
###xml 64 66 64 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 67 69 67 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 93 95 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r38">38</xref>
###xml 167 171 167 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 222 226 222 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 374 376 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r39">39</xref>
###xml 377 379 371 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r42">42</xref>
###xml 386 390 380 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 512 514 500 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r43">43</xref>
###xml 515 517 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r44">44</xref>
###xml 659 661 647 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r45">45</xref>
###xml 662 664 650 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r46">46</xref>
###xml 841 842 829 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 843 845 831 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r47">47</xref>
###xml 846 848 834 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r48">48</xref>
###xml 855 859 843 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 986 988 968 970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r49">49</xref>
###xml 989 991 971 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r55">55</xref>
###xml 1101 1103 1077 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r56">56</xref>
###xml 1104 1106 1080 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r57">57</xref>
###xml 570 578 <span type="species:ncbi:9606">patients</span>
Contrary to these findings, a decreased risk of NTG in Chinese [13,14] and POAG in Japanese [38] has been reported whereas some investigators reported no link between APOE polymorphisms and glaucoma. Besides glaucoma, the APOE epsilon4 allele has been identified as a genetic susceptibility factor for a variety of neurodegenerative disorders in diverse ethnic populations [39-42]. The APOE epsilon4 allele has also been associated with early age-at-onset of Alzheimer's Disease (AD) in a dose-dependent manner [43,44]. Interestingly, a high incidence of glaucoma in AD patients clearly suggests a close association between these neurodegenerative disorders [45,46]. It has been hypothesized that the cellular mechanisms involved in the degeneration of optic nerve cells in glaucoma are quite similar to the neurodegenerative changes in AD [9,47,48]. The APOE epsilon4 allele is also strongly linked with increased risk of Parkinson disease, schizophrenia, and coronary artery disease [49-55]. Possession of the epsilon4 allele is also associated with a retarded recovery after traumatic head injury [56,57].
###end p 55
###begin p 56
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r49">49</xref>
###xml 825 829 735 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 952 954 856 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r58">58</xref>
###xml 985 987 889 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r59">59</xref>
###xml 393 401 <span type="species:ncbi:9606">patients</span>
###xml 572 579 <span type="species:ncbi:9606">patient</span>
###xml 778 785 <span type="species:ncbi:9606">patient</span>
APOE alleles modulate the biological functions of APOE in part by altering the binding of the different lipoprotein lipid classes [49]. Individuals carrying the epsilon4 allele have higher plasma and neuronal levels of cholesterol as compared to individuals with the epsilon2 or epsilon3 allele. The higher frequency of the epsilon3/epsilon3 genotype in controls when compared to the glaucoma patients indicated a protective effect of epsilon3/epsilon3 against the development of glaucoma in Saudis. On the other hand, the epsilon4/epsilon4 genotype was only found in the patient group with a complete absence in the normal Saudi population, suggesting its association with POAG. The genotypes epsilon2/epsilon2, epsilon2/epsilon3, and epsilon2/epsilon4 were absent in both the patient and control groups. Earlier studies on APOE polymorphisms in the general population also showed the absence of genotypes containing the epsilon2 allele among Saudis [58] as well as Native Americans [59].
###end p 56
###begin p 57
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 329 337 <span type="species:ncbi:9606">patients</span>
The results of this study suggest that APOE alleles may influence the risk of POAG but has no effect on the susceptibility of PACG. The inheritance of the epsilon4 allele is associated with elevated risk of POAG but not of PACG, and epsilon3 may exert protection against POAG. However, further studies involving larger number of patients are warranted to reach a definite conclusion.
###end p 57
###begin title 58
Acknowledgments
###end title 58
###begin p 59
The authors would like to thank S. Sadaf Rizvi for her help in laboratory work.
###end p 59
###begin title 60
References
###end title 60
###begin article-title 61
###xml 10 16 <span type="species:ncbi:9606">people</span>
Number of people with glaucoma worldwide.
###end article-title 61
###begin article-title 62
Open-angle glaucoma.
###end article-title 62
###begin article-title 63
Recent advances in molecular genetics of glaucomas.
###end article-title 63
###begin article-title 64
Glaucoma: the damage caused by pressure. XLVI Edward Jackson memorial lecture.
###end article-title 64
###begin article-title 65
Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey.
###end article-title 65
###begin article-title 66
Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription.
###end article-title 66
###begin article-title 67
Apolipoprotein E is synthesized in the retina by Muller glial cells, secreted into the vitreous, and rapidly transported into the optic nerve by retinal ganglion cells.
###end article-title 67
###begin article-title 68
The apolipoprotein epsilon4 gene is associated with elevated risk of normal tension glaucoma.
###end article-title 68
###begin article-title 69
Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene.
###end article-title 69
###begin article-title 70
Frequencies of apolipoprotein E polymorphism in a healthy Kurdish population from Kermanshah, Iran.
###end article-title 70
###begin article-title 71
Apolipoprotein E gene polymorphism and serum lipid levels in the Guangxi Hei Yi Zhuang and Han populations.
###end article-title 71
###begin article-title 72
###xml 107 115 <span type="species:ncbi:9606">patients</span>
SNPs and interaction analyses of myocilin, optineurin, and apolipoprotein E in primary open angle glaucoma patients.
###end article-title 72
###begin article-title 73
Association of apolipoprotein E polymorphisms with normal tension glaucoma in a Chinese population.
###end article-title 73
###begin article-title 74
The role of apolipoprotein E gene polymorphisms in primary open-angle glaucoma.
###end article-title 74
###begin article-title 75
Normal tension glaucoma is not associated with the common apolipoprotein E gene polymorphisms.
###end article-title 75
###begin article-title 76
###xml 35 43 <span type="species:ncbi:9606">patients</span>
Apolipoprotein E polymnorphisms in patients with primary open-angle glaucoma.
###end article-title 76
###begin article-title 77
The definition and classification of glaucoma in prevalence surveys.
###end article-title 77
###begin article-title 78
Prevalence and causes of blindness in the rural population of the Chennai Glaucoma study.
###end article-title 78
###begin article-title 79
Refractive errors in an older population: the Blue Mountains Eye Study.
###end article-title 79
###begin article-title 80
New diagnostic criteria for diabetes mellitus: are we any further forward?
###end article-title 80
###begin article-title 81
###xml 62 70 <span type="species:ncbi:9606">patients</span>
Histocompatability antigens in vitiligo: Hamburg study on 102 patients from Northern Germany.
###end article-title 81
###begin article-title 82
HLA and disease--a survey.
###end article-title 82
###begin article-title 83
Apolipoprotein E polymorphism in a Danish population compared to findings in 45 other study populations around the world.
###end article-title 83
###begin article-title 84
Antrhopology of the apolipoprotein E (Apo E) gene: low frequency of Apo E4 allele in Basques and in tribal (Baiga) populations of India.
###end article-title 84
###begin article-title 85
Apolipoprotein B, apolipoprotein E, and angiotensin-converting enzyme polymorphisms in 2 Italian populations at different risk for coronary artery disease and comparison of allele frequencies among European population.
###end article-title 85
###begin article-title 86
Apolipoprotein E polymorphism in India: high APOE*E3 allele frequency in Ramgarhia of Punjab.
###end article-title 86
###begin article-title 87
APOE distribution in world populations with new data from India and the UK.
###end article-title 87
###begin article-title 88
Association between apolipoprotein E polymorphism an Alzheimer disease in Tehran, Iran.
###end article-title 88
###begin article-title 89
Apolipoprotein E gene polymorphism in the Mongolian population.
###end article-title 89
###begin article-title 90
Apolipoprotein distribution around the world. Is APOE 4 a thrifty allele?
###end article-title 90
###begin article-title 91
Effects of apolipoprotein E genotypes on the development of exfoliation syndrome.
###end article-title 91
###begin article-title 92
Differential effects of apolipoprotein E3 and E4 on neuronal growth in vitro.
###end article-title 92
###begin article-title 93
Alzheimer's disease, and recovery from brain stress.
###end article-title 93
###begin article-title 94
A study on the association of apolipoprotein E genotypes with primary open-angle glaucoma and primary angle-closure glaucoma in northeast of China.
###end article-title 94
###begin article-title 95
Apolipoprotein E gene polymorphisms and retinal vascular signs: the atherosclerosis risk in communities (ARIC) study.
###end article-title 95
###begin article-title 96
Iijima h, Tsukahara S. The apolipoprotein E gene polymorphism is associated with open angle glaucoma in the Japanese population.
###end article-title 96
###begin article-title 97
Epsilon 4 allele of apolipoprotein E increases risk of Alzheimer's disease in a Chinese population.
###end article-title 97
###begin article-title 98
Effects of apolipoprotein E on dementia and aging in the Shanghai Survey of Dementia.
###end article-title 98
###begin article-title 99
Apoliporpotein E epsilon 2 may be a risk factor for sporadic frontotemporal dementia.
###end article-title 99
###begin article-title 100
Apolipoprotein E genotype and Alzheimer's disease in Hong Kong elderly Chinese.
###end article-title 100
###begin article-title 101
Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Metal Analysis Consortium.
###end article-title 101
###begin article-title 102
Evaluation of polymorphisms in the presenilin-1 gene and the butyrylcholinesterase gene as risk factors in sporadic Alzheimer's disease.
###end article-title 102
###begin article-title 103
###xml 55 63 <span type="species:ncbi:9606">patients</span>
Severe progression of glaucomatous optic neuropathy in patients with Alzheimer's disease.
###end article-title 103
###begin article-title 104
Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer's disease and Parkinson's disease.
###end article-title 104
###begin article-title 105
Glaucoma: ocular Alzheimer's disease?
###end article-title 105
###begin article-title 106
Hypothesis for a common basis for neuroprotection in glaucoma and Alzheimer's disease: anti-apoptosis by alpha-2-adrenergic receptor activation.
###end article-title 106
###begin article-title 107
Apolipoprotein E and Alzheimer's disease.
###end article-title 107
###begin article-title 108
Apolipoprotein E e4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases.
###end article-title 108
###begin article-title 109
Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease.
###end article-title 109
###begin article-title 110
Gene dose of apolipoprotein E type-4 allele and the risk of Alzheimer's disease in late onset families.
###end article-title 110
###begin article-title 111
###xml 65 73 <span type="species:ncbi:9606">patients</span>
Apolipoprotein E type epsilon 4 allele frequency is increased in patients with schizophrenia.
###end article-title 111
###begin article-title 112
Bai Sa, Shen T, Yu A, Xue H, St Clair D, He L. Association of APOE gene with schizophrenia in Chinese: a possible risk factor in times of malnutrition.
###end article-title 112
###begin article-title 113
Phenotypic associations of tau and ApoE in Parkinson's disease.
###end article-title 113
###begin article-title 114
Association of apolipoprotein E polymorphism with outcome after head injury.
###end article-title 114
###begin article-title 115
Glaucoma genetics, present and future.
###end article-title 115
###begin article-title 116
Apolipoprotein E polymorphism in Saudis.
###end article-title 116
###begin article-title 117
Apolipoprotein E polymorphism in the Indian and Mestizo population of Mexico.
###end article-title 117

